D3-GHR Polymorphism and Turner Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00443144|
Recruitment Status : Completed
First Posted : March 5, 2007
Last Update Posted : December 3, 2015
The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.
Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).
|Condition or disease||Intervention/treatment|
|Turner Syndrome Short Stature||Drug: recombinant human growth hormone|
|Study Type :||Observational|
|Official Title:||D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||May 2007|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00443144
|Tübingen, Germany, 72076|
|Principal Investigator:||Gerhard Binder, M.D. PhD||University-Children's Hospital Tübingen|